Singapore, April 15 -- Israel-based Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, has announced a research collaboration agreement with Ramot at Tel Aviv University - Tel Aviv University's technology transfer company - to evaluate Galmed's brain-penetrating SCD1 inhibitor, Aramchol, as a targeted therapy for metastatic brain cancer.  

By combining the genomic expertise of the Ben-David Lab with the advanced 3D in vitro and in vivo modeling capabilities of the Satchi-Fainaro Lab (both TAU internationally renowned research labs), Galmed aims to validate Aramchol's efficacy in treating p53-deficient brain metastases.

The findings from the new research would also s...